Abstract:Jianmin Gong, 1, 2, &ast Bo Shi, 1, 3, &ast Ping Yang, 1 Adeel Khan, 4 Tao Xiong, 2 Zhiyang Li 1 1 Department of Clinical Laboratory, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210000, People's Republic of China; 2 College of Life Science, Yangtze University, Jingzhou, 434025, People's Republic of China; 3 Department of Clinical Laboratory, Nanjing Jiangning Hospital of Chinese Medicine (CM), Nanjing, 211100, People's Republic of China; 4 Department of Biotechnology, University of Science and Technology Bannu, Bannu, 28100, Islamic Republic of Pakistan &astThese authors contributed equally to this work Correspondence: Tao Xiong, College of Life Science, Yangtze University, Jingzhou, 434025, People's Republic of China, Tel +8613872387410, Email Zhiyang Li, Department of Clinical Laboratory, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, People's Republic of China, Tel +8618951703765, Email Background: Hypertrophic cardiomyopathy (HCM) is a dominantly inherited disease associated with sudden immune cell associations that remain unclear. The aim of this study was to comprehensively screen candidate markers associated with HCM and immune cells and explore potential pathogenic pathways. Methods: First, download the GSE32453 dataset to identify differentially expressed genes (DEGs) and perform Gene Ontology and pathway enrichment analysis using DAVID and GSEA. Next, construct protein-protein interaction (PPI) networks using String and Cytoscape to identify hub genes. Afterward, use CIBERSORT to determine the proportion of immune cells attributed to key genes in HCM and conduct ROC analysis based on the external dataset GSE36961 to evaluate their diagnostic value. Finally, validate the expression of key genes in the hypertrophic cardiomyocyte model through qRT-PCR using data from the HPA database. Results: Comprehensive analysis revealed that there were 254 upregulated genes and 181 downregulated genes in HCM. The enrichment study underscored pathways of inflammatory signaling, including MAPK and PI3K-Akt pathways. Pathways abundant in genes associated with HCM encompassed myocardial contraction and NADH dehydrogenase activity. Additionally, the analysis of immune infiltration revealed a notable increase in macrophages, NK cells, and monocytes in the HCM group, showing statistically significant variances in CD4 memory resting T cell infiltration when compared to the healthy control group. Within the validation dataset GSE36961, the Area Under the Curve (AUC) scores for eight crucial genes (FOS, CD86, CD68, BDNF, PIK3R1, PLEK, RAC2, CCL2) each exceeded 0.8. The HPA database revealed the positioning traits and paths of these eight crucial genes in smooth muscle cells, myocardial cells, and fibroblasts. The outcomes of the qRT-PCR were aligned with the sequencing findings. Conclusion: Bioinformatics analysis unveiled pivotal genes, pathways, and immune involvement, illuminating the molecular underpinnings of HCM. These findings suggest promising therapeutic targets for clinical applications. Keywords: hypertrophic cardiomyopathy, bioinformatic, immune cells infiltration, biomarker Hypertrophic cardiomyopathy (HCM) is a heterogenic genetic disease most commonly caused by sarcomeric mutations that lead to left ventricular hypertrophy, fibrosis, hypercontractility and reduced compliance. 1 The intricate nature of hypertrophic cardiomyopathy involves a combination of diastolic dysfunction, myocardial ischaemia, and outflow tract obstruction and arrhythmias caused by the displacement of the mitral valve in the front. From a clinical standpoint, the symptomatology exhibits a wide range, encompassing no discernible symptoms as well as palpitations, dyspnoea, diminished exercise capacity, chest discomfort, syncope, and even abrupt demise. 2 Epidemiological studies indicate that at least 1 in every 500 individuals is affected by hypertrophic cardiomyopathy, while 1 in every 200 individuals is either affected by it or has a genetic predisposition. 3 Despite functional and genome-wide association studies (GWAS) suggesting an association between the FHOD3 gene and myocardial hypertrophy, no pathogenic variants directly related to hypertrophic cardiomyopathy have been identified. 4 While significant progress has been made in the diagnosis through the use of echocardiography, clinical diagnosis still faces several challenges, including the diversity of clinical manifestations, uncertainty in imaging exa -Abstract Truncated-

Identification of Underlying Hub Genes Associated with Hypertrophic Cardiomyopathy by Integrated Bioinformatics Analysis

Pgpm_a_314880 823..837

Identification of Key Modules and Hub Genes in Hypertrophic Cardiomyopathy Based on Integrative Weighted Gene Co-expression Network Analysis

Identification of Biomarkers Correlated with Hypertrophic Cardiomyopathy with Co-Expression Analysis.

Weighted Gene Co-Expression Network Analysis Identified Underlying Hub Genes and Mechanisms in the Occurrence and Development of Viral Myocarditis

Transcriptomics data integration and analysis to uncover hallmark genes in hypertrophic cardiomyopathy

Identification of novel key genes and signaling pathways in hypertrophic cardiomyopathy: evidence from bioinformatics and next generation sequencing data analysis

Identification of Circulating Hub Long Noncoding RNAs Associated with Hypertrophic Cardiomyopathy Using Weighted Correlation Network Analysis

Integration of Transcriptomic Data Identifies Key Hallmark Genes in Hypertrophic Cardiomyopathy

Identification of hub genes associated with diabetic cardiomyopathy using integrated bioinformatics analysis

A personalized mRNA signature for predicting hypertrophic cardiomyopathy applying machine learning methods

A novel strategy for key gene identification in hypertrophic cardiomyopathy based on cuproptosis and multiple WGCNA analyses

Bioinformatics and Immune Infiltration Analyses Reveal the Key Pathway and Immune Cells in the Pathogenesis of Hypertrophic Cardiomyopathy

Identification of ATRNL1 and WNT9A as novel key genes and drug candidates in hypertrophic cardiomyopathy: integrative bioinformatics and experimental validation

Identification of Potential miRNA-mRNA Regulatory Network Contributing to Hypertrophic Cardiomyopathy (HCM)

Identification and validation of pyroptosis-related genes as potential biomarkers for hypertrophic cardiomyopathy: A comprehensive bioinformatics analysis

Integrated Analysis of Hub Genes and Mirnas in Dilated Cardiomyopathy

Systemic Bioinformatic Analyses Of Nuclear-Encoded Mitochondrial Genes In Hypertrophic Cardiomyopathy

Unveiling Immune Infiltration Characterizing Genes in Hypertrophic Cardiomyopathy Through Transcriptomics and Bioinformatics

Genetic Dissection of Hypertrophic Cardiomyopathy with Myocardial RNA-Seq

Integrative analysis of transcriptome, DNA methylome, and chromatin accessibility reveals candidate therapeutic targets in hypertrophic cardiomyopathy